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Abstract
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the viral envelope
glycoprotein (Env) only a few of these antibodies possess the capacity to neutralize a broad range of strains. The induction
of such antibodies represents an important goal in the development of a preventive vaccine against the infection. Among
the broadly neutralizing monoclonal antibodies discovered so far, three (2F5, Z13 and 4E10) target the short and hidden
membrane proximal external region (MPER) of the gp41 transmembrane protein. Antibody responses to MPER are rarely
observed in HIV-infected individuals or after immunization with Env immunogens. To initiate antibody responses to MPER in
its membrane-embedded native conformation, we generated expression plasmids encoding the membrane-anchored
ectodomain of gp41 with N-terminal deletions of various sizes. Following transfection of these plasmids, the MPER domains
are displayed on the cell surface and incorporated into HIV virus like particles (VLP). Transfected cells displaying MPER
mutants bound as efficiently to both 2F5 and 4E10 as cells transfected with a plasmid encoding full-length Env. Mice
immunized with VLPs containing the MPER mutants produced MPER-specific antibodies, the levels of which could be
increased by the trimerization of the displayed proteins as well as by a DNA prime-VLP boost immunization strategy.
Although 2F5 competed for binding to MPER with antibodies in sera of some of the immunized mice, neutralizing activity
could not be detected. Whether this is due to inefficient binding of the induced antibodies to MPER in the context of wild
type Env or whether the overall MPER-specific antibody response induced by the MPER display mutants is too low to reveal
neutralizing activity, remains to be determined.
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Introduction
The HIV envelope glycoprotein complex mediates virus entry
into the cell [1] and represents the only exposed viral protein
on the surface of the virion. The precursor envelope glycopro-
tein gp160 is cleaved into two subunits, the gp120 surface
protein that interacts with receptor (CD4) and co-receptor
(CCR5 or CXCR4) and the gp41 transmembrane protein,
which anchors the gp160 into the membrane of the virion.
After binding of trimers of the mature envelope proteins to the
receptors, gp41 inserts its fusion peptide into the cytoplasmic
membrane of the target cell, then collapses to form the stable
six-helix bundle, bringing closely together viral and cell
membranes [2,3]. The tryptophan-rich membrane proximal
external region then mediates fusion of the two membranes
allowing the viral core to enter the cell [2,4].
The MPER is a hydrophobic and tryptophan-rich portion of the
gp41 ectodomain close to the lipid membrane. The structure of
MPER peptide in a lipid environment (dodecylphosphocholine
micelles), revealed an ‘‘L’’ shaped structure with two alpha helices
separated by a hinge region [5]. Most of the hydrophobic residues
on the same side of the peptide are imbedded into the
phospholipid membrane. In the six helix bundle situation and in
the presence of the fusion-peptide proximal region, Buzon and co-
workers described a helical rod-like structure on the N-terminal
side of MPER with a ,90u turn of the MPER chain at Asn 687
(numbering according to Gen bank entry AF128126.3). The
adjacent Trp-Leu-Trp-Tyr sequence was perpendicular to the
rod-like structure [4]. Liu and co-workers described a labile a-
helical trimeric structure of the MPER spanning residues 672–693
[6]. These observations suggest that the MPER within the
functional envelope spike adopts a complex structure including
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workers [7,8], that may influence the epitope conformation
recognized by MPER-targeted neutralizing antibodies.
The MPER is a well-conserved sequence [5] that bears epitopes
for three broadly neutralizing antibodies (bnAb) [9], disseminated
on a 22 amino acid long peptide. The 2F5 core epitope
(ELDKWA) is N-terminal to the 4E10 core epitope (NWFDIT),
and the Z13 epitope overlaps both 2F5 and 4E10 epitopes [10–
13]. The MPER is intensively studied as it represents one of the
most interesting targets for HIV vaccine research [14]. Both 4E10
and 2F5 monoclonal neutralizing Abs were obtained from PBMC
of HIV-1 infected individuals, while Z13 was obtained from an
antibody phage display library prepared from bone marrow of an
HIV-1 infected donor [13]. However, antibodies to the epitopes
recognized by these three broadly neutralizing monoclonal
antibodies are rarely detected in HIV infected subjects [15,16],
a situation that may be explained by several factors including
sterical occlusion due to bulky gp120 domains, intensive glycosyl-
ation, or immune diversion by more immunogenic decoy
structures [17]. When the MPER peptide is expressed as a fusion
protein or displayed on various surfaces, MPER peptide-specific
antibodies can be induced [18–21]. However, results from these
studies indicate that these MPER peptide-specific antibodies have
rarely neutralizing activity, suggesting that the right conformation
of MPER is important [18]. Rather than grafting MPER into
heterologous scaffold proteins, we explored in the present study
whether one could increase the accessibility of MPER by deleting
large parts of the N-terminal regions of gp41. The C-terminal
membrane anchorage was preserved in order not to disturb the
embedding of the peptide in the lipid membrane.
Materials and Methods
Animals
Six to eight week-old female Balb/c mice were purchased from
Janvier (Le Genest-ST-Isle, France) and housed in singly ventilated
cages in accordance with the national law and institutional
guidelines.
Cloning of the Mutants
MPER mutants were generated by standard PCR amplification
techniques, using six different forwards primers that bind the gp41
upstream near the MPER, and a reverse primer that binds the 39-
end of gp41. The clade B-derived HIV-1 envelope R2 [22] in
which the intracellular domain was substituted by that of VSV-G
was used as PCR template. The open reading frame of the MPER
display mutants also encoded at the N-terminus the mouse IL-7
leader peptide followed by a GCN4 isoleucine zipper [23], an
Ollas-tag [24] and a G4S flexible linker. Constructs lacking the
GCN4 isoleucine zipper were also generated. The open reading
frames were cloned between the CMV promoter and the BGH
polyadenylation signal of the pVax 200-DEST vector (Invitrogen).
Transient Transfection of HEK293T Cells
HEK293T cells transfection was performed using polyethyleni-
mine [25]. Briefly, cells were seeded to reach 90% confluency at
the time of transfection. For a 75 cm
2 flask, 2.1 ml of DMEM
medium was placed in a 10 ml tube, DNA plasmid was distributed
into the medium and mixed. Polyethylenimine (PEI) working
solution (1 mg/ml in H2O, pH7) was added to a ratio of 1 mg
plasmid DNA for 1.5 ml PEI (w/v), the mixture was vortexed
thoroughly and incubated 10 minutes at room temperature (RT).
The medium in the tissue culture dishes was replaced by fresh
medium containing 2% FBS and 0.25 mg/ml Gentamycin, then
the transfection mixture was added and the dish was gently
swirled, and incubated at 37uC, 5% CO2 in humidified
atmosphere. Six to eight hours later, the medium was replaced
again with fresh medium containing 2% FBS and 0.25 mg/ml
gentamycin and cells were incubated for 24 to 48 hours.
FACS Analysis of Transfected Cells
HEK293T cells were transfected as describe above with the
different MPER display mutants or env expression plasmids. At 36
hours after transfection, cells were detached from the tissue culture
flask using a scraper and gently re-suspended by pipetting up and
down. The cells were thereafter pelleted at 800 g for 10 minutes
and washed three times with 0.5% PBS-BSA buffer. Subsequently,
2.0610
5 cells were added per well of 96 round-bottom-well plate,
centrifuged at 2500 RPM and the supernatant discarded. 100 mlo f
the first Ab (2F5, 4E10 or 3D6, Polymun Scientific, Vienna)
diluted in PBS-BSA were added, the cells were resuspended and
incubated for 45 minutes at room temperature. The cells were
then washed three times, and 100 ml of the fluorescently labeled
secondary Ab diluted in PBS-BSA were added, mixed and
incubated 30 minutes at RT. Cells were then washed four times
and resuspended in 400 ml of PBS-BSA and analyzed using FACS
Calibur (Becton Dickinson). FACS data were later analyzed using
FlowJo software.
Production of Virus Like Particles
For virus like particles (VLP) production, transfections were
carried out in 175 cm
2 flasks using 20 mg of plasmids expressing
MPER display mutant, gp41 or the R2 env and 20 mg of the gag-pol
plasmid HgpSyn [26]. Supernatants were harvested 36 to 48 hours
post transfection, cleared by low speed centrifugation (800 g, 10
minutes at 4uC), filtered through 0.45 mm filter and carefully
loaded on the top of 5 ml of 20% sucrose cushion into 25689 mm
open-top Polyclear centrifuge tubes (SETON). The filled tubes
were balanced and centrifuged for 3 hours at 25,000 rpm and 4uC
in a SW28 rotor (Beckman). Pellets obtained were re-suspended in
250 mlo f1 6PBS and stored at 280uC.
Western Blot Analysis
VLP samples were prepared by adding an equal volume of 26
sample buffer (130 mM Tris-Cl, pH8.0; 20% (v/v) Glycerol; 9.2%
(w/v)SDS;0.02%bromophenolblue;2%DTT),priortoheatingat
95uCfor15minutes,vortexingfor5secondsandcoolingonicefor5
minutes.Separation was performed in 15%acrylamide, 0.1% SDS
gels for 9 to 12 hours at 50volts and 4uC. For the non-denaturing
condition,theSDSwasomittedfromthesamplebufferandsamples
wereloadedwithoutpriorheatingon15%acrylamidegelcontaining
0.1%SDS.Afterblotting,membraneswereblockedfor1houratRT
in 5% milk (5 g of milk powder in 100 ml PBS-T) under gentle
shaking,brieflywashedwithPBS-T(0.1%Tween20in16PBS)and
incubated for two hours with the primary antibody. Afterwards the
membrane was washed three times (365 minutes under gentle
shaking), incubated 1 hour with goat polyclonal anti-human IgG-
HRP (Sigma-Aldrich, Taufkirchen, Germany) and then washed
threetimes.Proteinbandswerevisualizedinaluminometerequipped
with a Hamamatsu CCD camera (model C2400-75H-01, Hama-
matsu Photonics K.K., Japan) after incubating the membrane with
reconstitutedECLchemiluminescentsolution(AlphaInnotech,San
Leandro, USA).
Confocal Microscopy of VLPs
GFP-labeled VLPs were prepared by co-transfection of
HEK293T cells in 25 cm
2 flask with 1 mg of the gag-pol expression
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pGag-eGFP (Cat. No. 11468, NIH AIDS reference and reagent
program) with 2 mg of plasmids expressing either the MPER42
mutant, gp41, or R2 env. The supernatant (5 ml) was harvested 48
hours post transfection and cleared as described above. To analyze
the MPER content of the VLPs, the supernatants were incubated
for 30 minutes at room temperature under gentle shaking with
1 mg/ml of 4E10 antibody conjugated with Alexa Fluor 647
(Invitrogen, Oregon, USA). VLPs were recovered from the
supernatant by ultracentrifugation through a 20% sucrose cushion
and resuspended in 250 mlo f1 6PBS. Slides for confocal analysis
were prepared by mixing 5 ml of the resuspended VLPs with 5 ml
of Prolong gold antifade reagent (Invitrogen, Oregon, USA) on
clean 76626 mm slides (Menzel GmbH, Braunschweig, Ger-
many). The mixed drop was then carefully covered with an
18618 mm cover-slide (Menzel GmbH, Braunschweig, Ger-
many). The slide was kept in the dark for at least 24 hours prior
to analysis on Leica DM IRE2 confocal laser scanning microscope
(LSM) (Leica Microsystems GmbH, Wetzlar, Germany). Confocal
fluorescent images were obtained using a 636objective followed
by a 46 digital magnification with the Leica confocal software.
Green and red fluorescent images were collected after sequential
excitation at 488 nm (eGFP) and 633 nm (Alexa Fluor 647).
Images were then analyzed using the ImageJ software (NIH,
http://rsbweb.nih.gov/ij/download.html) to generate overlays of
the green and red fluorescent signals. This involved contrast
enhancement of the images, but the same conditions were applied
for all the images analyzed. The frequency of the co-localization of
Alexa Fluor 647 positive spots with a GFP positive spot was
determined by manual counting.
ELISA
Characterization of VLPs. The ELISA plates (LIA plates,
Greiner Bio-one, Frickenhausen, Germany) were coated with the
different VLP preparations or a recombinant gp41 standard (NIH
AIDS Research and Reference Reagent Program, Germantown,
USA) and detected using the 4E10 antibody and a HRP-labeled
anti-human secondary antibody (Dako, Glostrup, Denmark).
Relative light units (RLU) obtained with dilutions of gp41
standard were used to generate a calibration curve which enabled
quantification of the MPER-Env content of VLP preparations.
Antibody detection in mouse serum. ELISA plates were
coated with 200 ng/well of synthetic MPER peptides (NEQEL-
LELDKWANLWNWFDISNWLWYIK, ProImmune, Oxford,
UK), and blocked with 1X rotiblock (Carl ROTH, Karlsruhe,
Germany). Serum was added at 1/100 dilution in 100 ml of 0.16
rotiblock, incubated 2 hours at RT. After 3 washing steps, bound
antibodies were detected using polyclonal Rabbit anti-mouse-Ig
HRP-labeled antibody (Dako, Glostrup, Denmark) and the ECL
substrate. For the competitive ELISA, binding of a 1:100 dilution
of the sera in presence or absence of 8 mg/ml of 2F5 or 3D6
monoclonal antibodies was analyzed.
Figure 1. Map of domains and amino acid sequences of the MPER display mutants. The open reading frames of the MPER display mutants
contain a heterologous leader peptide (LP), an isoleucine zipper to promote trimerization, a common tag (Ollas-tag) for easy detection, a flexible
linker region (G4S), various regions of gp41 (MPERmut) including an HIV-1 transmembrane region (TM), and the cytoplasmic domain of the VSV-G
protein (CT). The amino acid sequence of the different domains is given in the one-letter code. The numbering backward as depicted indicates the
number of MPER-derived amino acid residues expressed by each mutant. The target regions for 2F5 and 4E10 monoclonal antibodies are indicated by
double arrow-lines.
doi:10.1371/journal.pone.0038068.g001
Targeting Antibodies to MPER of HIV Envelope
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e38068DNA Electroporation
Female Balb/c mice were first anesthetized with 50 mg/kg of
Ketamin and 10 mg/kg of Xylazin, and the hind legs shaved. The
electroporator device (Ichor Medical Systems Inc, San Diego,
USA.) was assembled as indicated by the manufacturer. The
syringe containing the DNA solution (300 mg/ml formulated in
16PBS) was inserted into position in the middle of the TriGrid
TM
electrode array, the array was inserted into the muscle of the
shaved hind leg, and 50 ml of DNA solution was delivered followed
by an electric pulse. The injection was repeated in the second hind
leg, and each mouse received a total volume of 100 ml equivalent
to 30 mg of plasmid DNA. Mice were vaccinated two or three
times at 4 weeks interval.
VLP Immunization
VLP aliquots were thawed from 280uC and diluted in 16PBS
to a concentration of 2 mg/ml of MPER Env-mutant or gp41.
50 ml of diluted VLP solution were injected subcutaneously into
the footpad of each hind leg, thereby administering 200 ng of
MPER protein per mouse. Mice were vaccinated three times at 4
weeks interval.
Sampling
Three weeks after each immunization, mice were bled under
general anesthesia by exposing them briefly to isofluran (Paragos,
Frankfurt, Germany) vapors, and then 15 drops of blood were
drawn from the retro-orbital sinus using a glass capillary tube.
Blood samples were kept at RT for two hours, centrifuged at
4500 g and the serum was collected and stored at 220uC.
Neutralization Assay in TZM-bl Cells
MN.3 clade B pseudotyped virus particles were produced by
cotransfecting HEK293T/17 cells with 4 mg of an HIV-1 rev/env
expression plasmid and 8 mgo fa nenv-deficient HIV-1 backbone
Figure 2. Surface expression of the MPER display mutants. (A) HEK293T cells transfected with expression plasmids encoding the different
MPER display mutants were stained with 2F5 (top panel) and 4E10 (bottom panel) antibodies and analyzed by flow cytometry. Representative
histograms of at least three independent transfection experiments are shown. (B) Mean fluorescence intensities (MFI) for the different MPER display
mutants are expressed as percentage of the MFI obtained with gp160 Env.
doi:10.1371/journal.pone.0038068.g002
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(Roche, Mannheim, Germany). Plasmid details are given in the
specimen catalog (number 4293) of the website of the HIV
Specimen Cryorepository (GHRC): http://ghrc-portal.ibmt.
fraunhofer.de/GHRC/welcome.do. Pseudovirus-containing su-
pernatant was harvested 48 h following transfection and clarified
by 0.45 mm filtration. Single-use aliquots (1.0 ml) were stored at
280uC. Virus stocks were diluted to an infectious dose yielding
a RLU value of approximately 150,000 following infection of
TZM-bl cells [27]. The virus particles were incubated with sera or
control antibodies in a total volume of 100 ml for 1 hour at 37uC,
and then TZM-bl cells diluted to 1610
5 cells per ml in DMEM
medium supplemented with FCS (10%), gentamicin (50 mg/ml)
and DEAE-Dextran (25 mg/ml) were added to each well. The
plate was covered and incubated 48 hours at 37uC, 5% CO2 in
a humidified atmosphere.
To measure the luciferase expression, supernatants were
carefully removed and 50 ml of Glo lysis buffer (Promega GmbH,
Mannheim, Germany) was added to each well and the plate was
incubated 5 minutes at RT. The supernatant from lysed cells was
pipetted up and down five times, and then transferred to a white
microtiter plate (Greiner bio-one, Frickenhausen, Germany). 50 ml
of Bright Glo reconstituted buffer were added to each well and the
RLU was measured within 3 minutes.
Results
Design and Characterization of MPER Display Mutants
To focus the antibody response to MPER in its native
conformation, large deletion mutants of gp41 expression plasmids
were generated encoding only 18, 24, 27, 32, 37, or 42 of the most
membrane proximal amino acids of the ectodomain of gp41
(Fig. 1). For efficient display of MPER on the cell membrane and
on the surface of virus-like particles, the MPER sequences were
flanked by a leader peptide at the N-terminus and a C-terminal
transmembrane domain of HIV-gp41 fused to the intracytoplas-
mic domain of VSV-G. To further mimic the natural conforma-
tion and to facilitate detection of the different MPER mutants,
a trimerization domain and a peptide tag (Ollas-Tag) were also
included. The MPER sequences were separated from the N-
terminal heterologous sequences by a flexible linker to facilitate
folding of MPER into its native conformation.
To determine expression and accessibility of MPER, HEK293T
cells were transfected with the different MPER display mutants
and stained with 4E10 and 2F5 antibodies for flow cytometric
analysis (Fig. 2A). The mean fluorescence intensities for cells
transfected with the MPER display mutants were generally higher
than those observed after transfection of the parental gp41
expression plasmid and similar in magnitude to the full-length Env
(Fig. 2B). As expected from the deletion of the 2F5 core epitope,
the MPER18 mutant was only detected by the 4E10 antibody,
while expression of DEnv, which lacks the entire MPER could
neither be detected by 4E10 nor by 2F5. The trimerization
domain did not affect expression and accessibility, since trans-
fection of MPER18, MPER24 and MPER42 mutants lacking the
trimerization domain resulted in similar staining intensities as
observed for the parental MPER display mutants (data not shown).
Incorporation of MPER Display Mutants into VLPs
Since we aimed to analyze the immunogenicity of MPER
display mutants by immunization with VLPs, the incorporation of
the different MPER mutants into particles was analyzed. VLPs
were partially purified from the supernatants of HEK293T cells
cotransfected with HIV-1 gag-pol expression plasmid and the
Figure 3. Incorporation of MPER display mutants into VLPs.
VLPs containing MPER display mutants were concentrated from the
supernatant of transfected cells and analyzed by Western blot analysis
under denaturing (A to C) and non-reducing conditions (D) using the
antibodies 2F5 (A), 4E10 (B), anti-Ollas (C, D). Results shown in Figures 3
A-D are representative of at least three WB analyses using different VLP
preparations and different denaturing conditions.
*MPER47 contains 5
amino acids residue of non-MPER origin at its N-terminus.
doi:10.1371/journal.pone.0038068.g003
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termined by Western blot analysis using 2F5, 4E10 and anti-Ollas
antibodies (Fig. 3A-B-C).
The predicted molecular weight as calculated by Vector NTI
program (Invitrogen) ranged between ,18.5 kD for MPER18 and
,21.3 kD for MPER42. None of the Western blot bands observed
confirmed these predictions. For each of the MPER mutant three
bands of higher electrophoretic mobility were observed (Fig. 3A-B-
C). The apparent molecular weights of these three bands gradually
increased with the numbers of MPER amino acids encoded by the
MPER18 mutant up to the MPER37 mutant (Fig. 3A-B-C). For
the MPER42 mutant, however, the electrophoretic mobility is
substantially higher than the one observed for the MPER37
mutant. The results obtained are consistent for the three
antibodies 2F5, 4E10, and anti-Ollas used for the detection of
the MPER display mutants. Under non-reducing conditions,
a larger band appears for all the mutants with approximately three
times the apparent molecular weight of the smaller band obtained
for each MPER mutant under stringent denaturing conditions
(Fig. 3A-B-C). These results suggest substantial differences in
electrophoretic mobility due to conformational differences associ-
Figure 4. Co-localization of MPER42 with VLPs. VLPs were generated by co-transfection of the indicated env expression plasmids and a gag-gfp
(green) expression plasmid and stained with 4E10 antibody. The percentage of red spots (n=350 to 499 per sample) that co-localize with green spots
is indicated.
doi:10.1371/journal.pone.0038068.g004
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MPER.
To obtain further evidence for incorporation of MPER mutants
into VLPs rather than exosome like vesicles, the MPER42 mutant
was cotransfected with a gag-gfp expression plasmid. The super-
natant of the transfected cells was then incubated with fluores-
cently-labeled 4E10 antibody conjugated to Alexa Fluor 647.
VLPs were pelleted through a 20% sucrose cushion and imaged by
confocal microscopy. Co-localization of 70.1% of the Alexa Fluor
647 positive spots with GFP positive particles indicated in-
corporation of the MPER42 mutant into VLPs (Fig. 4B). For
control VLPs lacking MPER a co-localization was observed in less
than 17.5% of the Alexa Fluor 647 positive spots representing the
background staining (Fig. 4A). The MPER42 mutant was
incorporated with higher frequency than gp41 (40.5%) (Fig. 4C),
and with comparable frequency as the wild type Env (73.3%)
(Fig. 4D).
Immunogenicity of MPER Display Mutants After DNA
Prime-VLP Boost Immunization
Although the different MPER mutants did not differ sub-
stantially in accessibility to 4E10 and 2F5 (with the exception of
MPER18), the Western blot analyses suggested different con-
formations. We therefore explored in a pilot immunization
experiment in mice whether the MPER18, MPER24 and
MPER42 mutants would induce different levels of MPER-specific
antibodies. In addition, the MPER24 and MPER42 mutants
lacking the trimerization domain (MPER24DTRIM, MPER42D-
TRIM) were included to explore a potential influence of the
trimerization domain on the immunogenicity.
Mice were first immunized three times by intramuscular
electroporation of DNA vaccines encoding the different MPER
mutants (Fig. 5A). Although we had previously observed that two
intramuscular electroporations of DNA vaccines encoding HA of
Figure 5. Antibody response after VLP boost in DNA immu-
nized mice. (A) Mice were immunized three times with DNA encoding
different MPER display mutants and boosted with VLPs containing the
different MPER display mutants eight to fifteen weeks after the last DNA
immunization. (B) MPER-specific antibody levels in the sera of
immunized mice three weeks after the last VLP immunization are
presented as log10 values of the relative light units (Log RLU) obtained
in an MPER antibody ELISA. Mean and single values for each of the
animals are shown.
doi:10.1371/journal.pone.0038068.g005
Figure 6. Influence of DNA priming on the MPER-specific
antibody response after the VLP boost. (A) Mice (n=5–6/group)
were immunized with VLPs containing different MPER display mutant
either with or without prior DNA immunization with plasmids encoding
the same MPER display mutants. (B) MPER-specific antibody levels in the
sera of immunized mice three weeks after the last VLP immunization are
presented as Log values of the relative light units (Log RLU) obtained in
an MPER antibody ELISA. Mean and single values for each of the animals
are shown. Statistically significant differences between the groups
treated with the different DNA and VLP vaccines were determined by
one way analysis of variance followed by Bonferroni’s multiple
comparison test and are indicated by horizontal bars with ‘‘a’’ indicating
a p-value of ,0.05. T-tests were performed to determine whether DNA
priming enhances antibody levels for each of the different immuno-
gens. Statistically significant differences are marked by dashed
horizontal bars with ‘‘b’’ indicating a p-value of ,0.05. Filled symbols
are used for non-primed mice and opened symbols for DNA-primed
mice. (C) Time course of MPER-specific antibodies in sera of individual
mice (MPER42-1 to MPER42-5) immunized with MPER42 DNA and VLP
vaccines.
doi:10.1371/journal.pone.0038068.g006
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specific antibodies [28], MPER-specific antibody responses
remained undetectable even after the third DNA immunization.
Therefore, the mice were further boosted three times by VLPs
containing the same MPER display mutants used for the DNA
immunizations (Fig. 5A). Three weeks after the last VLP
immunization, MPER-specific antibody responses could be
detected in all animals immunized with MPER display mutants
containing the trimerization domain. In contrast, MPER specific
antibody responses after immunization with MPER24DTRIM
and MPER42DTRIM were only seen in a single mouse (Fig. 5B).
To confirm the induction of MPER-specific antibody responses
and to determine the contribution of the DNA immunizations on
the antibody responses seen after the VLP booster immunizations,
mice were vaccinated with MPER24, MPER42, gp41 and full
length Env gp160 containing VLPs with or without prior DNA
priming immunizations (Fig. 6A).
As observed previously, DNA immunization alone did not
induce detectable MPER-specific Ab response (data not shown
and Fig. 6C). After the third VLP immunization, MPER-specific
Ab responses were detectable in all animals that had been primed
by DNA vaccination (Fig. 6B). VLP immunization alone also
induced MPER-specific antibodies, but the levels were generally
lower and some of the mice did not respond. As observed in the
previous immunization experiment (Fig. 5B), the MPER42 display
mutant tended to induce the highest MPER-specific antibody
response (Fig. 6B). In two of the mice of the MPER42 group, the
MPER-specific antibody response was more than 10-fold higher
than the one observed following immunization with full-length
gp160. For this group, MPER-specific antibodies were also
analyzed longitudinally demonstrating a substantial increase in
MPER-specific antibody levels after the second VLP immuniza-
tion in two of the immunized mice (Fig. 6C).
Characterization of the MPER-specific Antibody Response
To determine whether the MPER-specific antibodies induced
by MPER42 DNA-VLP immunization could compete for binding
with 4E10 and 2F5, sera were tested in the MPER peptide ELISA
in the presence or absence of an excess of 4E10 and 2F5. The
monoclonal antibody 3D6 binding to an epitope of gp41, which
does not overlap with the MPER peptide used in the ELISA, was
used as a negative control. Analyzing the sera with the highest
MPER-specific antibody response, 2F5, but not 3D6 or 4E10 (data
not shown) competed for binding to the MPER peptide (Fig. 7A)
suggesting that antibodies were induced that either recognize or
overlap the 2F5 epitope.
The same sera were also analyzed for neutralizing activity using
the TZM-bl pseudotype assay [27] and compared to the
neutralizing activity of sera from mice responding to DNA prime
VLP boost immunization with gp41 or gp160 vaccines. No
evidence of neutralization could be observed with the sera from
MPER42 or gp41 immunized mice (Fig. 7B). Weak neutralization
activity with a 50% neutralization titer of 1/25 was observed with
the serum from the mouse immunized with gp160 vaccines.
Discussion
Display of N-terminal deletion mutants of gp41 on the surface
of cells increases 2F5 and 4E10 binding compared to gp41 (Fig. 2).
This does not seem to be due to higher expression levels of MPER
display mutants, since the VLPs contain at least as much of gp41
as of the MPER display mutants (Fig. 3). Thus, the accessibility of
the MPER display mutants appears to be higher than the
accessibility of gp41. To allow direct comparison of the properties
of gp41 with those of the MPER display mutants, the gp41 was
also expressed with an N-terminal leader sequence, the trimeriza-
tion domain, the ollas-tag, and the flexible linker region. These
modifications may explain why cells expressing wild type Env
show higher binding of 2F5 and 4E10 than cells expressing the
modified gp41. More importantly, the binding activity of 2F5 and
4E10 to cells expressing wild type Env was similar to cells
expressing the MPER display mutants, confirming their efficient
expression. Since 4E10 and 2F5 were selected for this study based
on their efficient binding to MPER in the context of wild type Env,
it is likely that the binding of these two monoclonal antibodies to
MPER is not sterically blocked. Therefore, it is not expected that
removing bulky domains can actually increase the binding of these
two monoclonal antibodies. Both monoclonal antibodies contain
unusual long complementary determining regions (CDR), which
are important for their binding to MPER in the context of wild
type Env [29]. Therefore, the removal of N-terminal domains of
the gp41 ectodomain from immunogens might allow the induction
of a much broader panel of MPER-specific antibodies including
those lacking long CDRs.
Figure 7. Characterization of the MPER-specific antibody
response. (A) Binding of antibodies in sera of mice immunized with
MPER42 by the DNA-VLP regimen to MPER peptide in the presence of
saturating amounts of 2F5 and 3D6 monoclonal antibodies. Significant
competition of 2F5 with serum antibodies from five individual mice
(MPER42-1 to MPER42-5) for binding to MPER peptide is marked by the
bars. (B) Neutralizing activity of sera of two individual mice with the
strongest antibody response after immunization with MPER42 DNA and
VLP vaccines. Sera from a DEnv control mouse and from mice
responding strongest to immunization with gp41 and gp160 by the
DNA-VLP regimen were also analyzed. The 2F5 antibody at a concen-
tration of 50 mg/ml was diluted as indicated and used as a positive
control for neutralization.
doi:10.1371/journal.pone.0038068.g007
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the MPER display mutants induce antibodies binding to the
MPER peptide. The addition of a trimerization domain increased
the MPER-specific antibody response, which might be either due
to fixation of the MPER in its relevant native conformation or
more efficient cross-linking of B-cell receptors leading to stronger
activation of MPER-specific B cell clones. Immunization with the
MPER42 display mutant induced in a subset of animals more than
10-fold higher anti-MPER antibody levels than immunization with
wild type Env. The absence of other immunodominant epitopes in
the MPER42 display mutant or better accessibility of the
MPER42 display mutant for the B cell receptor on the surface
of MPER-specific B cells may explain the observed difference in
the MPER-specific antibody response. However, it should be
noted that the strong MPER-specific antibody response was only
observed in two of the five mice demonstrating substantial
variability in the response to the same immunogen.
One important question is whether MPER display mutants
induce antibodies binding to MPER in the context of wild type
Env. Attempts to determine the binding activity of sera from mice
immunized with MPER display mutants to wild type Env
expressed on the surface of transfected cells were not successful
(data not shown), since immunization with VLPs also induced
antibodies against cellular proteins resulting in high background
staining. Therefore, several possibilities remain, why the MPER
peptide-specific antibodies induced by immunization with the
MPER display mutants had no neutralizing activity. Firstly, the
sensitivity of the MPER peptide ELISA could be higher than the
sensitivity of the neutralization assay. Thus, the MPER-specific
antibody levels induced might be too low to be detected in the
neutralization assay. Secondly, the induced MPER-specific anti-
bodies bind to MPER peptides but not to the native conformation
of MPER. Given the design of the MPER-display mutants we
consider this unlikely but cannot exclude this possibility. Thirdly,
the MPER-specific antibodies induced by immunization with the
MPER display mutants recognize MPER in its natural confor-
mation, but their binding to MPER in the context of wild type Env
is blocked by bulky domains of gp120 or gp41. Although we do not
have direct evidence for the third possibility, this seems to be an
inherent theoretical limitation of our approach and many other
MPER peptide or mimotope-based HIV vaccination strategies.
The neutralization mechanism of 2F5 and 4E10 antibodies have
been described as a two-step ‘‘encounter-docking’’ process [5,30]
in which the antibodies weakly interact first with the lipid
membrane, and then with its core-epitope extracted from the
lipid membrane [5,31]. The weak interaction involves the long
hydrophobic CDR-H3 loop that characterizes the 2F5 and 4E10
broadly neutralizing antibodies [32]. The deletion of this CDR-H3
loop has been shown to abrogate the ability of 2F5 to neutralize
HIV, but not to bind free MPER peptides [29], suggesting that the
antibodies induced by vaccination should reproduce this particular
CDR-H3 loop to possess the ability to neutralize.
After immunization with immunogens displaying an exposed
MPER, high affinity antibodies to MPER can probably be raised
without the need for long CDR-H3s. Thus, in the absence of a wild
type Env immunogen there is no positive selection of B cells
producing MPER-specific antibodies with long CDR-H3s. If it
holds true, that long CDRs are required for binding of antibodies
to MPER in the context of wild type Env, the induction of
substantial levels of such antibodies by immunization with
immunogens displaying an exposed MPER should be the
exception rather than the rule.
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